In this podcast and accompanying article, we talked with Dr. Paul Wotton, Chief Executive Officer, Obsidian Therapeutics about the evolution of cancer therapy and new advancements in the space including precision medicine. Our discussion included Obsidian’s cytoDRiVE™ platform that provides a technology, in which the level and timing of protein activity are fully controlled in […]

Vericel (NSDQ:VCEL) said yesterday it inked an exclusive U.S. licensing and supply agreement with MediWound (NSDQ:MDWD) for its NexoBrid biological product, and reported first quarter earnings that missed expectations on Wall Street. The NexoBrid is a topically-administered product intended to enzymatically remove nonviable burn tissue in patients with deep partial and full-thickness thermal burns. The product has already […]

Cancer therapy development has advanced to researching targeted immunotherapies and are moving into gene-specific therapies.  Some companies, however, are focusing on reviving cytotoxic therapies that were too toxic for patients when administered generally. These companies are developing targeted transportation mechanisms to deliver cytotoxic release at tumor cells while minimizing overall toxicity to patients. Bill Newell, Chief […]